Advertisement

Personalized Pathway-Activated Systems Imaging in Oncology

Principal and Instrumentation

  • Tomio Inoue
  • David Yang
  • Gang Huang

Table of contents

  1. Front Matter
    Pages i-xii
  2. Chemical Biology Aspect

    1. Front Matter
      Pages 1-1
    2. Ming-Rong Zhang
      Pages 3-15
    3. Lan V. Pham, Jerry L. Bryant, David Yang, Richard J. Ford
      Pages 17-42
  3. Engineering and Instrumentation Aspect

    1. Front Matter
      Pages 53-53
    2. Taiga Yamaya, Hideaki Tashima
      Pages 55-84
    3. Wai-Hoi Wong, Yuxuan Zhang
      Pages 85-101
  4. Social Aspect

    1. Front Matter
      Pages 103-103
    2. Wenbin Ma, Sara Herrera-Rodriguez, Hector Martinez-Valdez
      Pages 127-150
  5. Clinical Aspect

    1. Front Matter
      Pages 151-151
    2. Kanae Kawai Miyake, Yuji Nakamoto
      Pages 171-184
    3. Tomohiro Kaneta, Tomio Inoue
      Pages 185-194
    4. Hiroaki Kurihara
      Pages 195-211
    5. Shao-Li Song, Pan-Li Li, Gang Huang
      Pages 213-222
    6. Skye Hsin-Hsien Yeh, Fan-Lin Kong, Ming-Hsien Lin
      Pages 233-243

About this book

Introduction

This comprehensive volume covers radiopharmaceuticals developed for pathway-directed systems in imaging and theranostic applications. We now are at the cutting edge of providing personalized treatment with increased use in oncology of these new radiopharmaceuticals. Trends in high-resolution instrumentation development, quality assurance systems and regulatory compliance for radiopharmaceuticals, clinical evaluation of radiopharmaceuticals, and benefits and pitfalls of the current clinical FDG PET are discussed.

Radiopharmaceuticals are used for diagnosis of diseases of the central nervous and cardiovascular systems and for staging, restaging, and treatment planning for cancers. Nuclear biomarkers allow precise measurement of molecular pathways on a whole-body image upon administration of functional radiolabeled agents, and nuclear imaging agents have potential use in patient selection, pharmacokinetic, dosage-finding, and proof-of-concept studies. Nuclear imaging agents and hybrid instrumentation also provide sensitive and specific answers for differential responsiveness in therapeutic outcome.

This book serves as a reference for moving the discovery and development of radiopharmaceuticals from the workbench to clinical applications. It thus benefits not only clinicians but also translational research scientists—molecular biologists, chemists, imaging scientists, pharmaceutical developers, physicists, and support staff.

Keywords

Radiopharmaceutical Theranostic Personalized treatment FDG PET Nuclear biomarker Nuclear imaging

Editors and affiliations

  • Tomio Inoue
    • 1
  • David Yang
    • 2
  • Gang Huang
    • 3
  1. 1.School of MedicineYokohama City UniversityYokohamaJapan
  2. 2.Vyripharm BiopharmaceuticalsUniversity of Texas Health Science CenterHoustonUSA
  3. 3.Renji Hospital / Department of Nuclear MedicineShanghai Jiao Tong UniversityShanghaiChina

Bibliographic information

  • DOI https://doi.org/10.1007/978-981-10-3349-0
  • Copyright Information Springer Nature Singapore Pte Ltd. 2017
  • Publisher Name Springer, Singapore
  • eBook Packages Medicine
  • Print ISBN 978-981-10-3348-3
  • Online ISBN 978-981-10-3349-0
  • Buy this book on publisher's site